## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.9% below STRENGTH zone (4.0-10.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($52.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. JP Morgan 2026 Preview: Bristol Myers Squibbâ€™s Continued Growth**
- Source: Pharmaceutical Executive | 20251224T142812 | Bullish | Relevance: 100%
- Bristol Myers Squibb (BMS) is focusing on a diversified portfolio and pipeline execution in oncology, cardiovascular, and neuroscience to drive sustained growth post-loss-of-exclusivity. The company's strategy involves incremental growth across multiple assets and therapeutic areas rather than relying on a single blockbuster. 2024 and 2025 were characterized by groundwork laying, cost discipline, and acquisition integration, setting the stage for more consistent growth in 2026 and beyond.

**2. Bristol-Myers (BMY) offers Eliquis free to Medicaid patients under new pricing pact**
- Source: MSN | 20251223T220852 | Somewhat-Bullish | Relevance: 100%
- This article is a placeholder with incomplete content. It states that Bristol-Myers (BMY) will offer Eliquis free to Medicaid patients due to a new pricing agreement. However, the body of the article is missing, preventing further details or context.

**3. Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)**
- Source: ts2.tech | 20251223T200852 | Neutral | Relevance: 100%
- Bristol-Myers Squibb (BMY) stock is facing scrutiny due to a Supreme Court bid challenging Medicare drug price negotiations and increasing competition in the oHCM market, despite an FDA approval of a competitor. The company is heading into 2026 with a raised dividend and various drug-pricing agreements, alongside ongoing debates about its valuation amidst policy risks and post-patent challenges. Investors are weighing these factors, with analyst opinions divided between "Buy" and "Hold" ratings.

**4. Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds (NYSE:BMY)**
- Source: Seeking Alpha | 20251224T142000 | Somewhat-Bullish | Relevance: 100%
- Bristol-Myers Squibb (BMY) is presented as a contrarian buy for dividend hunters due to its discounted valuations, strong cash flows, and secure dividends, despite facing growth headwinds from patent cliffs for key drugs like Opdivo and Eliquis. While the company's "Growth Portfolio" temporarily offsets declines, future results may be pressured by these expiries and Medicaid changes, particularly from FY2026 onwards. The author suggests patience for potential investors, advising to wait for a moderate retracement given the stock's recent overbought technical indicators and mixed investment thesis.

**5. Bristol-Myers Squibb stock holds Buy rating at Guggenheim amid oHCM competition**
- Source: Investing.com | 20251224T020852 | Bullish | Relevance: 100%
- Guggenheim has reiterated a Buy rating and $62.00 price target on Bristol-Myers Squibb (NYSE:BMY) following the approval of a competing treatment for obstructive hypertrophic cardiomyopathy (oHCM). Despite new competition, Guggenheim believes Bristol-Myers Squibb's Camyzos maintains a strong position due to comparable treatment requirements, similar drug-drug interaction profiles, and extensive real-world evidence from two Phase 3 studies. BMY offers attractive fundamentals, including a 4.61% dividend yield sustained for 55 years, and strong stock momentum with low volatility.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.4B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.1 |
| Current P/E | 8.4 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.1% to 3.9% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.1pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.1% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.94% (CS: 89) | Neutral |
| RSI_14 | 69.8 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.134x | Above |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.72
- **Stop Loss:** $52.32 (4.4% risk)
- **Target:** $57.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 500
- **Position Value:** $27,360.00
- **Portfolio %:** 27.36%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*